Insulatard Flexpen

Insulin Human, the active ingredient in Insulatard Flexpen, is an insulin presented as a pen injector for subcutaneous use. It provides basal insulin therapy to lower blood glucose levels in patients with diabetes, including both Type 1 and Type 2 diabetes mellitus.

GNH USA supplies Insulatard Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, sourcing the product from EU‑authorized manufacturers. The product complies with EU quality standards and is distributed under strict temperature‑controlled conditions, ensuring consistent potency and safety for patients.

Insulatard Flexpen is an intermediate‑acting insulin used to provide basal glucose control in diabetes management.

Type 1 diabetes mellitus: supplies basal insulin to maintain stable blood glucose levels. Type 2 diabetes mellitus: used as basal insulin when oral agents are insufficient to achieve glycemic targets. Hyperglycemia: reduces elevated blood glucose concentrations by promoting cellular uptake of glucose.

Insulatard Flexpen may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if dose exceeds needs. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight with prolonged insulin therapy. - Edema: mild fluid retention, often in lower extremities.

Serious or Rare Side Effects: - Severe hypoglycemia with seizures or loss of consciousness. - Allergic reactions: rash, urticaria, or anaphylaxis. - Lipodystrophy: abnormal fat accumulation or loss at injection sites. - Insulin antibody formation: may alter insulin effectiveness.

When using Insulatard Flexpen, several precautions should be observed to ensure safe and effective therapy.

- Dose individualization: adjust dose based on frequent blood glucose monitoring and clinical response. - Hypoglycemia risk: avoid administration when blood glucose is already low; treat promptly if symptoms occur. - Concomitant medications: monitor for additive hypoglycemic effects with sulfonylureas, meglitinides, or beta‑blockers. - Renal or hepatic impairment: may require dose reduction and closer monitoring. - Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulatard Flexpen can interact with other medicines, altering its glucose‑lowering effect or increasing adverse events.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use can cause severe hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms, requiring careful monitoring. - ACE inhibitors or ARBs: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycemia risk.

Moderate Interactions (Monitor Closely): - Corticosteroids: may raise blood glucose, necessitating insulin dose adjustments. - Thyroid hormones: can increase insulin requirements. - Alcohol: can potentiate insulin’s effect and cause unpredictable hypoglycemia.